Research protocols typically use daily dosing for 714 days during the induction phase, with therapeutic effects lasting 30+ days post-treatment despite complete plasma clearance within 12 hours of the final dose
~12-15 hours (endogenous circulating) ~1-2 hours (plasma) ~1-2 hours (estimated) ~1 hour (58-64 minutes) Variable (multi-compound blend) ~3+ hours (estimated, plasma) Unknown (topical peptide: no systemic PK data) Unknown (topical peptide: no systemic PK data available) Unknown (oral peptide complex, no published PK data) Unknown (oral peptide complex) Unknown (topical peptide: no systemic PK data available) Unknown (topical peptide: no systemic PK data available) No systemic PK data available (topical cosmeceutical) Not measurable systemically: acts locally in the intestinal lumen and is degraded within the GI tract Not measurable (minimal systemic absorption) ~15-30 seconds (rapid degradation by kininases) 25 minutes (normal renal function)
S100A8 lacks the ability of Ca 2+ -binding in the N-terminal EF-hand motif, due to the absence of Ca 2+ -coordination necessary amino acid residues
However, few people are aware of the role of vitamin B12 in supporting brain health and normal functioning
For best results, start with the dose that the manufacturer recommends
Beyond Barriers is confident the results will be more robust when delivered intranasally. Using a repurposed drug lets the company pursue the 505(b)(2) FDA approval pathway, which Kole says, has a three-fold better chance of success of approval than the traditional 505(b)(1) route and is less expensive and time-intensive. Administration doses and schedules are to be determined, but early research suggests the administration window may be as long as 72 hours after injury
